Contrast media for X-ray and magnetic resonance imaging: Development, current status and future perspectives

Investigative Radiology

Volumn 50, Issue 9, 2015, Pages 671-678

  Frenzel, Thomas ^a   Lawaczeck, Rüdiger ^b   Taupitz, Matthias ^c   Jost, Gregor ^a   Lohrke, Jessica ^a   Sieber, Martin A ^a   Pietsch, Hubertus ^a  

^a BAYER PHARMA AG   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

contrast media; gadolinium; imaging; iodine; iron oxide nanoparticles; relaxivity

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM; IODINE; LIPOSOME; METAL CHELATE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

DIAGNOSTIC IMAGING; HUMAN; MICELLE; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIOGRAPHY; RADIOLOGICAL PARAMETERS; RELAXATION EFFECT; REVIEW; COMPUTER ASSISTED TOMOGRAPHY; IMAGE ENHANCEMENT; PROCEDURES; TRENDS;

CONTRAST MEDIA; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; RADIOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84939515387     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0000000000000193     Document Type: Review

References (149)

1. Clauss W, Speck U,. Historical development of x-ray contrast media for urography and angiography. In: Vogl T, Clauß W, Li GZ, eds. Computed tomography. Berlin Heidelberg, Germany: Springer; 1996: 1-11.
2. Barrs TJ,. Overview of radiopaque drugs: 1895-1931. Am J Health Syst Pharm. 2006; 63: 2248-2255.
3. Swick M,. Darstellung der niere und harnwege im röntgenbild durch intravenöse einbringung eines neuen kontraststoffes, des uroselectans. Klin Wochenschr. 1929; 8: 2087-2089.
4. Pietsch H, Hübner-Steiner U, Seidensticker P,. X-ray contrast media. In: Ullmann's Encyclopedia of Industrial Chemistry. Weinheim, Germany: Wiley-VCH; 2012: 577-593.
5. Lenhard DC, Pietsch H, Sieber MA, The osmolality of nonionic, iodinated contrast agents as an important factor for renal safety. Invest Radiol. 2012; 47: 503-510.
6. Morcos SK,. Contrast-induced nephropathy: are there differences between low osmolar and iso-osmolar iodinated contrast media? Clin Radiol. 2009; 64: 468-472.
7. Jost G, Pietsch H, Lengsfeld P, The impact of the viscosity and osmolality of iodine contrast agents on renal elimination. Invest Radiol. 2010; 45: 255-261.
8. Dawson P, Cosgrove DO, Grainger RG,. Textbook of contrast media. Oxford, United Kingdom: Taylor & Francis Group; 1999.
9. Palkowitsch PK, Bostelmann S, Lengsfeld P,. Safety and tolerability of iopromide intravascular use: a pooled analysis of three non-interventional studies in 132,012 patients. Acta Radiol. 2014; 55: 707-714.
10. Wendt-Nordahl G, Rotert H, Trojan L, Intravenous contrast media in uroradiology: evaluation of safety and tolerability in almost 50,000 patients. Med Princ Pract. 2006; 15: 358-361.
11. Morisetti A, Tirone P, Luzzani F, Toxicological safety assessment of iomeprol, a new x-ray contrast agent. Eur J Radiol. 1994; 18 (suppl 1): S21-S31.
12. Bettmann MA, Heeren T, Greenfield A, Adverse events with radiographic contrast agents: results of the SCVIR contrast agent registry. Radiology. 1997; 203: 611-620.
13. Reddan D,. Patients at high risk of adverse events from intravenous contrast media after computed tomography examination. Eur J Radiol. 2007; 62 (suppl 0): 26-32.
14. Hunt CH, Hartman RP, Hesley GK,. Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: retrospective review of 456,930 doses. AJR Am J Roentgenol. 2009; 193: 1124-1127.
15. Idee JM, Pines E, Prigent P, Allergy-like reactions to iodinated contrast agents. A critical analysis. Fundam Clin Pharmacol. 2005; 19: 263-281.
16. van der Molen A,. Effects of iodine-based contrast media on thyroid function. In: Thomsen HS, Webb JAW, eds. Contrast media. Berlin Heidelberg, Germany: Springer; 2014: 157-165.
17. Stacul F, Bellin MF,. Late adverse reactions to iodine-based contrast media. In: Thomsen HS, Webb JAW, eds. Contrast media. Berlin Heidelberg, Germany: Springer; 2014: 141-146.
18. Pohly JP,. Onset of late adverse drug reactions to dimeric non-ionic contrast media: iotrolan, iodixanol. Pharmacoepidemiol Drug Saf. 1998; 7 (suppl 1): S18-S22.
19. Thomsen H, Stacul F, Webb JW,. Contrast medium-induced nephropathy. In: Thomsen HS, Webb JAW, eds. Contrast media. Berlin Heidelberg, Germany: Springer; 2014: 81-104.
20. McClennan BL,. Adverse reactions to iodinated contrast media. Recognition and response. Invest Radiol. 1994; 29 (suppl 1): S46-S50.
21. Katayama H, Yamaguchi K, Kozuka T, Adverse reactions to ionic and nonionic contrast media. A report from the Japanese committee on the safety of contrast media. Radiology. 1990; 175: 621-628.
22. Meurer K, Laniado M, Hosten N, Intra-Arterial and intravenous applications of iosimenol 340 injection, a new non-ionic, dimeric, iso-osmolar radiographic contrast medium: phase 2 experience. Acta Radiol. 2015; 56: 702-708.
23. Meurer K, Kelsch B, Hogstrom B,. The pharmacokinetic profile, tolerability and safety of the iodinated, non-ionic, dimeric contrast medium iosimenol 340 injection in healthy human subjects. Acta Radiol. 2015; 56: 581-586.
24. Wistrand LG, Rogstad A, Hagelin G, Ge-145, a new low-osmolar dimeric radiographic contrast medium. Acta Radiol. 2010; 51: 1014-1020.
25. Sachse A, Leike JU, Schneider T, Biodistribution and computed tomography blood-pool imaging properties of polyethylene glycol-coated iopromide-carrying liposomes. Invest Radiol. 1997; 32: 44-50.
26. Lusic H, Grinstaff MW,. X-ray-computed tomography contrast agents. Chem Rev. 2013; 113: 1641-1666.
27. Immordino ML, Dosio F, Cattel L,. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006; 1: 297-315.
28. Romano EL, Romano M,. Staphylococcal protein a bound to colloidal gold: a useful reagent to label antigen-Antibody sites in electron microscopy. Immunochemistry. 1977; 14: 711-715.
29. Ashton JR, Clark DP, Moding EJ, Dual-energy micro-CT functional imaging of primary lung cancer in mice using gold and iodine nanoparticle contrast agents: a validation study. PLoS One. 2014; 9. e88129.
30. Zeng C, Shi X, Wu B, Colloids containing gadolinium-capped gold nanoparticles as high relaxivity dual-modality contrast agents for CT and MRI. Colloids Surf B Biointerfaces. 2014; 123: 130-135.
31. Nebuloni L, Kuhn GA, Muller R,. A comparative analysis of water-soluble and blood-pool contrast agents for in vivo vascular imaging with micro-CT. Acad Radiol. 2013; 20: 1247-1255.
32. Lipshutz GS, Brennan TV, Warren RS,. Thorotrast-induced liver neoplasia: a collective review. J Am Coll Surg. 2002; 195: 713-718.
33. Kiessling F, Mertens ME, Grimm J, Nanoparticles for imaging: top or flop? Radiology. 2014; 273: 10-28.
34. Debbage P,. Targeted drugs and nanomedicine: present and future. Curr Pharm Des. 2009; 15: 153-172.
35. Longmire M, Choyke PL, Kobayashi H,. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond). 2008; 3: 703-717.
36. Torres AS, Bonitatibus PJ Jr, Colborn RE, Biological performance of a size-fractionated core-shell tantalum oxide nanoparticle x-ray contrast agent. Invest Radiol. 2012; 47: 578-587.
37. Hubbell JH, Seltzer SM, Tables of X-Ray Mass Attenuation Coefficients and Mass Energy-Absorption Coefficients (version 1.4). National Institute of Standards and Technology, Gaithersburg, MD; 2004. Available at: http://physics.nist.gov/xaamdi. Accessed June 12, 2015.
38. Yu SB, Watson AD,. Metal-based x-ray contrast media. Chem Rev. 1999; 99: 2353-2378.
39. Nowak T, Hupfer M, Brauweiler R, Potential of high-z contrast agents in clinical contrast-enhanced computed tomography. Med Phys. 2011; 38: 6469-6482.
40. Krause W, Mahler M, Hanke B, Dy-EOB-DTPA: tolerance and pharmacokinetics in healthy volunteers and preliminary liver imaging in patients. Invest Radiol. 2001; 36: 431-444.
41. Kalinowski M, Wagner HJ,. 1-molar gadobutrol as a contrast agent for digital subtraction angiography [in German]. Rofo. 2004; 176: 85-90.
42. Krause W, Schuhmann-Giampieri G, Bauer M, Ytterbium- and dysprosium-EOB-DTPA. A new prototype of liver-specific contrast agents for computed tomography. Invest Radiol. 1996; 31: 502-511.
43. Johnson TR, Krauss B, Sedlmair M, Material differentiation by dual energy CT: initial experience. Eur Radiol. 2007; 17: 1510-1517.
44. Krauss B, Grant KL, Schmidt BT, The importance of spectral separation: an assessment of dual-energy spectral separation for quantitative ability and dose efficiency. Invest Radiol. 2015; 50: 114-118.
45. Runge VM, Marquez H, Andreisek G, Recent technological advances in computed tomography and the clinical impact therein. Invest Radiol. 2015; 50: 119-127.
46. Roessl E, Brendel B, Engel K, Sensitivity of photon-counting based K-edge imaging in x-ray computed tomography. IEEE Trans Med Imaging. 2011; 30: 1678-1690.
47. Schlomka JP, Roessl E, Dorscheid R, Experimental feasibility of multi-energy photon-counting K-edge imaging in pre-clinical computed tomography. Phys Med Biol. 2008; 53: 4031-4047.
48. Dix WR, Kupper W, Dill T, Comparison of intravenous coronary angiography using synchrotron radiation with selective coronary angiography. J Synchrotron Radiat. 2003; 10 (Pt 3): 219-227.
49. Pan D, Schirra CO, Senpan A, An early investigation of ytterbium nanocolloids for selective and quantitative "multicolor" spectral CT imaging. ACS Nano. 2012; 6: 3364-3370.
50. Bech M, Jensen TH, Bunk O, Advanced contrast modalities for x-ray radiology: phase-contrast and dark-field imaging using a grating interferometer. Z Med Phys. 2010; 20: 7-16.
51. Pfeiffer F, Kottler C, Bunk O, Hard x-ray phase tomography with low-brilliance sources. Phys Rev Lett. 2007; 98: 108105.
52. Bech M, Tapfer A, Velroyen A, In-vivo dark-field and phase-contrast x-ray imaging. Sci Rep. 2013; 3: 3209.
53. Momose A, Yashiro W, Kido K, X-ray phase imaging: from synchrotron to hospital. Philos Trans A Math Phys Eng Sci. 2014; 372: 20130023.
54. Lawaczeck R, Diekmann F, Diekmann S, New contrast media designed for x-ray energy subtraction imaging in digital mammography. Invest Radiol. 2003; 38: 602-608.
55. Velroyen A, Bech M, Malecki A, Microbubbles as a scattering contrast agent for grating-based x-ray dark-field imaging. Phys Med Biol. 2013; 58: N37-N46.
56. de Haen C,. Conception of the first magnetic resonance imaging contrast agents: a brief history. Top Magn Reson Imaging. 2001; 12: 221-230.
57. Runge VM, Ai T, Hao D, The developmental history of the gadolinium chelates as intravenous contrast media for magnetic resonance. Invest Radiol. 2011; 46: 807-816.
58. Mendonca-Dias MH, Gaggelli E, Lauterbur PC,. Paramagnetic contrast agents in nuclear magnetic resonance medical imaging. Semin Nucl Med. 1983; 13: 364-376.
59. Runge VM, Clanton JA, Lukehart CM, Paramagnetic agents for contrast-enhanced NMR imaging: a review. AJR Am J Roentgenol. 1983; 141: 1209-1215.
60. Brasch RC, Weinmann HJ, Wesbey GE,. Contrast-enhanced NMR imaging: animal studies using gadolinium-DTPA complex. AJR Am J Roentgenol. 1984; 142: 625-630.
61. Weinmann HJ, Brasch RC, Press WR, Characteristics of gadolinium-dtpa complex: a potential NMR contrast agent. AJR Am J Roentgenol. 1984; 142: 619-624.
62. Solomon I,. Relaxation processes in a system of two spins. Phys Rev. 1955; 99: 559.
63. Bloembergen N, Morgan LO,. Proton relaxation times in paramagnetic solutions. Effects of electron spin relaxation. J Chem Phys. 1961; 34: 842-850.
64. Lauffer RB,. Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design. Chem Rev. 1987; 87: 901-927.
65. Tóth E, Helm L, Merbach A,. Relaxivity of gadolinium(III) complexes: theory and mechanism. In: Merbach A, Helm L and Tóth É eds. The chemistry of contrast agents in medical magnetic resonance imaging. Chichester, UK: John Wiley & Sons, Ltd; 2013: 25-81.
66. Hwang LP, Freed JH,. Dynamic effects of pair correlation functions on spin relaxation by translational diffusion in liquids. J Chem Phys. 1975; 63: 4017-4025.
67. Freed JH,. Dynamic effects of pair correlation functions on spin relaxation by translational diffusion in liquids. II. Finite jumps and independent T1 processes. J Chem Phys. 1978; 68: 4034-4037.
68. Caravan P, Ellison JJ, McMurry TJ, Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev. 1999; 99: 2293-2352.
69. Hermann P, Kotek J, Kubicek V, Gadolinium(III) complexes as MRI contrast agents: ligand design and properties of the complexes. Dalton Trans. 2008: 3027-3047.
70. Aime S, Crich SG, Gianolio E, High sensitivity lanthanide(III) based probes for MR-medical imaging. Coord Chem Rev. 2006; 250: 1562-1579.
71. Werner EJ, Kozhukh J, Botta M, 1,2-hydroxypyridonate/terephthalamide complexes of gadolinium (III): synthesis, stability, relaxivity, and water exchange properties. Inorg Chem. 2009; 48: 277-286.
72. Shen Y, Goerner FL, Snyder C, T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T. Invest Radiol. 2015; 50: 330-338.
73. Frenzel T, Lengsfeld P, Schirmer H, Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol. 2008; 43: 817-828.
74. Rohrer M, Bauer H, Mintorovitch J, Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005; 40: 715-724.
75. Weinmann HJ, Laniado M, Mutzel W,. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR. 1984; 16: 167-172.
76. Le Mignon MM, Chambon C, Warrington S, Gd-DOTA. Pharmacokinetics and tolerability after intravenous injection into healthy volunteers. Invest Radiol. 1990; 25: 933-937.
77. Van Wagoner M, Worah D,. Gadodiamide injection. First human experience with the nonionic magnetic resonance imaging enhancement agent. Invest Radiol. 1993; 28 (suppl 1): S44-S48.
78. Staks T, Schuhmann-Giampieri G, Frenzel T, Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest Radiol. 1994; 29: 709-715.
79. McLachlan SJ, Eaton S, De Simone DN,. Pharmacokinetic behavior of gadoteridol injection. Invest Radiol. 1992; 27 (suppl 1): S12-S15.
80. Aime S, Caravan P,. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging. 2009; 30: 1259-1267.
81. Swan SK, Baker JF, Free R, Pharmacokinetics, safety, and tolerability of gadoversetamide injection (Optimark) in subjects with central nervous system or liver pathology and varying degrees of renal function. J Magn Reson Imaging. 1999; 9: 317-321.
82. Schuhmann-Giampieri G, Mahler M, Röll G, Pharmacokinetics of the liver-specific contrast agent Gd-EOB-DTPA in relation to contrast-enhanced liver imaging in humans. J Clin Pharmacol. 1997; 37: 587-596.
83. Kirchin MA, Pirovano GP, Spinazzi A,. Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol. 1998; 33: 798-809.
84. Spinazzi A, Lorusso V, Pirovano G, Multihance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol. 1998; 5 (suppl 1): S86-S89; discussion S93-S94.
85. Rohrer M,. MRI contrast media-introduction and basic properties of the blood pool agent gadofosveset (Vasovist®). In: Leiner T, Goyen M, Rohrer M, eds. Clinical blood pool MR imaging. Berlin Heidelberg, Germany: Springer; 2008: 3-15.
86. Palkowitsch P, Voth M,. Summary of the safety data for gadobutrol and gadofosveset. Eur Radiol Suppl. 2008; 18: 47-53.
87. Matsumura T, Hayakawa M, Shimada F, Safety of gadopentetate dimeglumine after 120 million administrations over 25 years of clinical use. Magn Reson Med Sci. 2013; 12: 297-304.
88. Endrikat JS, Dohanish S, Balzer T, Safety of gadoxetate disodium: results from the clinical phase II-III development program and postmarketing surveillance. J Magn Reson Imaging. 2015. [Epub ahead of print].
89. Runge VM,. Safety of magnetic resonance contrast media. Top Magn Reson Imaging. 2001; 12: 309-314.
90. Kirchin MA, Runge VM,. Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging. 2003; 14: 426-435.
91. Herborn CU, Honold E, Wolf M, Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Invest Radiol. 2007; 42: 58-62.
92. Runge VM, Parker JR,. Worldwide clinical safety assessment of gadoteridol injection: an update. Eur Radiol. 1997; 7 (suppl 5): 243-245.
93. Kirchin MA, Pirovano G, Venetianer C, Safety assessment of gadobenate dimeglumine (multihance): extended clinical experience from phase I studies to post-marketing surveillance. J Magn Reson Imaging. 2001; 14: 281-294.
94. Marckmann P, Skov L, Rossen K, Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006; 17: 2359-2362.
95. Grobner T,. Gadolinium-A specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006; 21: 1104-1108.
96. Thomsen H,. Nephrogenic systemic fibrosis and gadolinium-based contrast media. In: Thomsen HS, Webb JAW, eds. Contrast media. Berlin Heidelberg, Germany: Springer; 2014: 207-217.
97. FDA 2007. Available at: http://www.fda.gov/downloads/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm154532.pdf2015. Accessed March 2, 2015.
98. EMEA 2009. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2009/11/WC500015569.pdf2015. Accessed March 2, 2015.
99. Thomsen HS, Morcos SK, Almen T, Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR contrast medium safety committee guidelines. Eur Radiol. 2013; 23: 307-318.
100. Port M, Idee JM, Medina C, Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals. 2008; 21: 469-490.
101. Eo Brücher, Tircsó G, Baranyai Z, Stability and toxicity of contrast agents. The chemistry of contrast agents in medical magnetic resonance imaging.: John Wiley & Sons, Ltd; 2013: 157-208.
102. Hao D, Ai T, Goerner F, MRI contrast agents: basic chemistry and safety. J Magn Reson Imaging. 2012; 36: 1060-1071.
103. Laurent S, Elst LV, Copoix F, Stability of MRI paramagnetic contrast media: a proton relaxometric protocol for transmetallation assessment. Invest Radiol. 2001; 36: 115-122.
104. Corot C, Robert P, Idée JM, Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev. 2006; 58: 1471-1504.
105. Stark DD, Weissleder R, Elizondo G, Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology. 1988; 168: 297-301.
106. Weissleder R, Hahn PF, Stark DD, Superparamagnetic iron oxide: enhanced detection of focal splenic tumors with MR imaging. Radiology. 1988; 169: 399-403.
107. R Weissleder, Stark, Engelstad B, Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol. 1989; 152: 167-173.
108. Weissleder R, Elizondo G, Wittenberg J, Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology. 1990; 175: 489-493.
109. Shen T, Weissleder R, Papisov M, Monocrystalline iron oxide nanocompounds (MION): physicochemical properties. Magn Reson Med. 1993; 29: 599-604.
110. Schellenberger EA, Bogdanov A Jr, Hogemann D, Annexin v-clio: a nanoparticle for detecting apoptosis by MRI. Mol Imaging. 2002; 1: 102-107.
111. Lawaczeck R, Bauer H, Frenzel T, Magnetic iron oxide particles coated with carboxydextran for parenteral administration and liver contrasting. Pre-clinical profile of sh u555a. Acta Radiol. 1997; 38 (4 Pt 1): 584-597.
112. Hamm B, Staks T, Taupitz M, Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide. J Magn Reson Imaging. 1994; 4: 659-668.
113. Bellin MF, Roy C, Kinkel K, Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles-initial clinical experience. Radiology. 1998; 207: 799-808.
114. Taupitz M, Schnorr J, Abramjuk C, New generation of monomer-stabilized very small superparamagnetic iron oxide particles (VSOP) as contrast medium for MR angiography: preclinical results in rats and rabbits. J Magn Reson Imaging. 2000; 12: 905-911.
115. Ludwig A, Poller WC, Westphal K, Rapid binding of electrostatically stabilized iron oxide nanoparticles to THP-1 monocytic cells via interaction with glycosaminoglycans. Basic Res Cardiol. 2013; 108: 328.
116. Wagner S, Schnorr J, Ludwig A, Contrast-enhanced MR imaging of atherosclerosis using citrate-coated superparamagnetic iron oxide nanoparticles: calcifying microvesicles as imaging target for plaque characterization. Int J Nanomedicine. 2013; 8: 767-777.
117. Helm L,. Optimization of gadolinium-based MRI contrast agents for high magnetic-field applications. Future Med Chem. 2010; 2: 385-396.
118. Dumas S, Jacques V, Sun WC, High relaxivity magnetic resonance imaging contrast agents. Part 1. Impact of single donor atom substitution on relaxivity of serum albumin-bound gadolinium complexes. Invest Radiol. 2010; 45: 600-612.
119. Jacques V, Dumas S, Sun WC, High-relaxivity magnetic resonance imaging contrast agents. Part 2. Optimization of inner- and second-sphere relaxivity. Invest Radiol. 2010; 45: 613-624.
120. Aime S, Botta M, Geninatti Crich S, Synthesis and NMR studies of three pyridine-containing triaza macrocyclic triacetate ligands and their complexes with lanthanide ions. Inorg Chem. 1997; 36: 2992-3000.
121. Raymond KN, Pierre VC,. Next generation, high relaxivity gadolinium MRI agents. Bioconjug Chem. 2005; 16: 3-8.
122. Port M, Corot C, Rousseaux O, P792: A rapid clearance blood pool agent for magnetic resonance imaging: preliminary results. MAGMA. 2001; 12: 121-127.
123. Vander Elst L, Raynal I, Port M, In vitro relaxometric and luminescence characterization of p792 (gadomelitol, Vistarem®), an efficient and rapid clearance blood pool MRI contrast agent. Eur J Inorg Chem. 2005; 2005: 1142-1148.
124. Ogan MD, Schmiedl U, Moseley ME, Albumin labeled with Gd-DTPA: an intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization. Invest Radiol. 1987; 22: 665-671.
125. Meyer D, Schaefer M, Chambon C, Paramagnetic dextrans as magnetic resonance blood pool tracers. Invest Radiol. 1994; 29: S90-S92.
126. Yan GP, Xu W, Yang L, Dextran gadolinium complexes as contrast agents for magnetic resonance imaging to sentinel lymph nodes. Pharm Res. 2010; 27: 1884-1892.
127. Misselwitz B, Schmitt-Willich H, Ebert W, Pharmacokinetics of gadomer-17, a new dendritic magnetic resonance contrast agent. MAGMA. 2001; 12: 128-134.
128. Marchand B, Douek PC, Benderbous S, Pilot MR evaluation of pharmacokinetics and relaxivity of specific blood pool agents for MR angiography. Invest Radiol. 2000; 35: 41-49.
129. Aime S, Botta M, Terreno E, Gd (DOTP) 5-outer-sphere relaxation enhancement promoted by nitrogen bases. Magn Reson Med. 1993; 30: 583-591.
130. Misselwitz B, Platzek J, Weinmann HJ,. Early MR lymphography with gadofluorine M in rabbits. Radiology. 2004; 231: 682-688.
131. Meding J, Urich M, Licha K, Magnetic resonance imaging of atherosclerosis by targeting extracellular matrix deposition with gadofluorine m. Contrast Media Mol Imaging. 2007; 2: 120-129.
132. Lanza GM, Winter PM, Caruthers SD, Magnetic resonance molecular imaging with nanoparticles. J Nucl Cardiol. 2004; 11: 733-743.
133. Sosnovik DE, Weissleder R,. Emerging concepts in molecular MRI. Curr Opin Biotechnol. 2007; 18: 4-10.
134. van Montfoort JE, Stieger B, Meijer DK, Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther. 1999; 290: 153-157.
135. Nunn AD, Linder KE, Tweedle MF,. Can receptors be imaged with MRI agents? Q J Nucl Med. 1997; 41: 155-162.
136. Kolodziej AF, Nair SA, Graham P, Fibrin specific peptides derived by phage display: Characterization of peptides and conjugates for imaging. Bioconjug Chem. 2012; 23: 548-556.
137. Overoye-Chan K, Koerner S, Looby RJ, EP-2104R: A fibrin-specific gadolinium-based MRI contrast agent for detection of thrombus. JACS. 2008; 130: 6025-6039.
138. Spuentrup E, Katoh M, Buecker A, Molecular MR imaging of human thrombi in a swine model of pulmonary embolism using a fibrin-specific contrast agent. Invest Radiol. 2007; 42: 586-595.
139. Uppal R, Ay I, Dai G, Molecular MRI of intracranial thrombus in a rat ischemic stroke model. Stroke. 2010; 41: 1271-1277.
140. Vymazal J, Spuentrup E, Cardenas-Molina G, Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: Results of a phase II clinical study of feasibility. Invest Radiol. 2009; 44: 697-704.
141. Wiener EC, Konda S, Shadron A, Targeting dendrimer-chelates to tumors and tumor cells expressing the high-Affinity folate receptor. Invest Radiol. 1997; 32: 748-754.
142. Sega E, Low P,. Tumor detection using folate receptor-Targeted imaging agents. Cancer Metastasis Rev. 2008; 27: 655-664.
143. Göhr-Rosenthal S, Schmitt-Willich H, Ebert W, The demonstration of human tumors on nude mice using gadolinium-labelled monoclonal antibodies for magnetic resonance imaging. Invest Radiol. 1993; 28: 789-795.
144. Aime S, Cabella C, Colombatto S, Insights into the use of paramagnetic Gd(III) complexes in MR-molecular imaging investigations. J Magn Reson Imaging. 2002; 16: 394-406.
145. Ye F, Wu X, Jeong EK, A peptide targeted contrast agent specific to fibrin-fibronectin complexes for cancer molecular imaging with MRI. Bioconjug Chem. 2008; 19: 2300-2303.
146. Bort G, Catoen S, Borderies H, Gadolinium-based contrast agents targeted to amyloid aggregates for the early diagnosis of Alzheimer's disease by MRI. Eur J Med Chem. 2014; 87: 843-861.
147. Burtea C, Laurent S, Murariu O, Molecular imaging of alpha v beta3 integrin expression in atherosclerotic plaques with a mimetic of RGD peptide grafted to Gd-DTPA. Cardiovasc Res. 2008; 78: 148-157.
148. Huang HM, Shih YY,. Pushing CT and MR imaging to the molecular level for studying the "omics": current challenges and advancements. Biomed Res Int. 2014; 2014: 365812.
149. Yen TC, Visvikis D, Pan T, Biomedical imaging: role and opportunities of medical imaging in the "omics" era. Biomed Res Int. 2014; 2014: 930213.